{"id":"NCT00520741","sponsor":"UCB BIOSCIENCES, Inc.","briefTitle":"Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures","officialTitle":"A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400 mg/Day Monotherapy in Subjects With Partial-onset Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-08","primaryCompletion":"2012-12","completion":"2012-12","firstPosted":"2007-08-27","resultsPosted":"2014-04-23","lastUpdate":"2018-07-19"},"enrollment":426,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Lacosamide","otherNames":["Vimpat"]},{"type":"DRUG","name":"Lacosamide","otherNames":["Vimpat"]}],"arms":[{"label":"Lacosamide 400 mg/day","type":"EXPERIMENTAL"},{"label":"Lacosamide 300 mg/day","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of this historical-controlled trial is to demonstrate the efficacy and safety of conversion to Lacosamide monotherapy in subjects with Partial-onset Seizures who are withdrawn from 1 to 2 marketed antiepileptic drugs.","primaryOutcome":{"measure":"Percentage of Subjects (Using Kaplan-Meier) Who Are Identified As Meeting At Least 1 Pre-defined Exit Criteria By Day 112 Relative To The Start of Withdrawal of Background Antiepileptic Drug(s)","timeFrame":"16 Weeks Maintenance Period (approximately 112 days)","effectByArm":[{"arm":"Lacosamide 400 mg/Day","deltaMin":30,"sd":null}],"pValues":[{"comp":"OG001","p":null}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":10},"locations":{"siteCount":158,"countries":["United States","Australia","Austria","Canada","Denmark","France","Germany","Ireland","Italy","Poland","Puerto Rico","Spain","United Kingdom"]},"refs":{"pmids":["24915838"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":106},"commonTop":["Dizziness","Headache","Nausea","Convulsion","Fatigue"]}}